Publications by authors named "Jolene Berg"

Claim this Profile
E
Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19.
Ravi Shankar P Singh, Robert R LaBadie, Sima S Toussi, Haihong Shi, Jolene Kay Berg

J Clin Pharmacol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis.
Sudhakar M Pai, Philip Chaikin, Jolene Kay Berg

J Clin Pharmacol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.
Matthew Sheetz, Philip Barrington, Sophie Callies, Paul H Berg, Juliet McColm, Jolene Berg

Br J Clin Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function.
Renli Teng, Sharen Muldowney, Yonggang Zhao, Jolene Kay Berg, Jonathan Lu

Eur J Clin Pharmacol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.
William B Smith, Jesse Hall, Jolene K Berg, Michal Kazimir, Amy Yamamoto

Clin Drug Investig· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
Jolene K Berg, Evan Tzanis, Lynne Garrity-Ryan, Stephen Bai, Surya Chitra

Antimicrob Agents Chemother· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.
Thomas C Marbury, Jolene Kay Berg, Leonard S Dove, Paul S Covington

J Clin Pharmacol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Robert W Townsend, Shahzad Akhtar, Harry Alcorn, Jolene K Berg, Donna L Kowalski

Eur J Clin Pharmacol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.
Takayuki Katsube, Roger Echols, Juan Camilo Arjona Ferreira, Heidi K Krenz, Jolene Kay Berg

J Clin Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.
Kimberly K Adkison, Jianjun Gan, Lucinda Elko-Simms, Stephen Gardner, Etienne Dumont, Jolene Berg

J Clin Pharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.
Amale Hawi, Harry Alcorn, Jolene Berg, Carey Hines, Howard Hait

BMC Nephrol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.
Julia Zack, Jolene Berg, Axel Juan, Nicola Pannacciulli, Martine Allard

Clin Pharmacol Drug Dev· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Peter Stein, Jolene K Berg, Linda Morrow, David Polidori, Eunice Artis

Metabolism· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.
Jolene Kay Berg, Eric H Kim, Benjamin Li, Bo Joelsson, Nader N Youssef

BMC Gastroenterol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes.
Joanne Sloan-Lancaster, Eyas Abu-Raddad, John Polzer, Jeffrey W Miller, Joel C Scherer, Jolene K Berg

Diabetes Care· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the fitness of human lysozyme transgenic dairy goats: growth and reproductive traits.
Kathryn A Jackson, Jolene M Berg, James D Murray, Elizabeth A Maga

Transgenic Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
Larissa A Wenning, William D Hanley, Diana M Brainard, Amelia S Petry, Kalyan Ghosh, Jolene K Berg

Antimicrob Agents Chemother· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis